Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations (Pediatric MATCH)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Armatti, Julie M; Doyle, Katherine M; Dubberly, Paige D; Parker, Melanie

  • IRB No: APEC1621M

    Protocol Abbrev: APEC1621M

    Principal Investigator: Amy A. Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621M

    Treatment: Drug: Tipifarnib

    Therapies Involved: Chemotherapy ID: NCT04284774

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with tipifarnib with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in HRAS.

  • Key Eligibility

    Sexes Eligible for Study - All
    Ages - 12 Months to 21 Years (Child, Adult)
    Accepts Healthy Volunteers - No